Literature DB >> 32553783

Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers.

Jun Fang1, Waliul Islam2, Hiroshi Maeda3.   

Abstract

The enhanced permeability and retention (EPR) effect is a unique phenomenon of solid tumors that is related to their particular anatomical and pathophysiological characteristics, e.g. defective vascular architecture; large gaps between endothelial cells in blood vessels; abundant vascular mediators such as bradykinin, nitric oxide, carbon monoxide, and vascular endothelial growth factor; and impaired lymphatic recovery. These features lead to tumor tissues showing considerable extravasation of plasma components and nanomedicines. These data comprise the basic theory underlying the development of macromolecular agents or nanomedicines. The EPR effect is not necessarily valid for all solid tumors, because tumor blood flow and vascular permeability vary greatly. Tumor blood flow is frequently obstructed as tumor size increases, as often seen clinically; early stage, small tumors show a more uniform EPR effect, whereas advanced large tumor show heterogeneity in EPR effect. Accordingly, it would be very important to apply enhancers of EPR effect in clinical setting to make EPR effect more uniform. In this review, we discuss the EPR effect: its history, factors involved, and dynamics and heterogeneity. Strategies to overcome the EPR effect's heterogeneity may guarantee better therapeutic outcomes of drug delivery to advanced cancers.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carbon monoxide; Heterogeneity; Nitric oxide; Nitroglycerin; Solid tumors; Tumor blood flow; Tumor-selective delivery; Vascular mediators; Vascular permeability

Mesh:

Substances:

Year:  2020        PMID: 32553783     DOI: 10.1016/j.addr.2020.06.005

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  66 in total

1.  Immunologically modified enzyme-responsive micelles regulate the tumor microenvironment for cancer immunotherapy.

Authors:  Zhimin Han; Chunai Gong; Juanjuan Li; Huanhuan Guo; Xinlu Chen; Yangli Jin; Shen Gao; Zongguang Tai
Journal:  Mater Today Bio       Date:  2021-12-04

2.  Radiation Cleaved Drug-Conjugate Linkers Enable Local Payload Release.

Authors:  Jeremy M Quintana; David Arboleda; Huiyu Hu; Ella Scott; Gaurav Luthria; Sara Pai; Sareh Parangi; Ralph Weissleder; Miles A Miller
Journal:  Bioconjug Chem       Date:  2022-07-14       Impact factor: 6.069

Review 3.  Surface-modified nanotherapeutics targeting atherosclerosis.

Authors:  Wenpan Li; Karina Marie Gonzalez; Jinha Chung; Minhyeok Kim; Jianqin Lu
Journal:  Biomater Sci       Date:  2022-09-27       Impact factor: 7.590

Review 4.  Targeting tumor vascularization: promising strategies for vascular normalization.

Authors:  Ruiqi Zheng; Feifan Li; Fengcen Li; Aihua Gong
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-19       Impact factor: 4.553

Review 5.  Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design.

Authors:  Qi Qiao; Xiong Liu; Ting Yang; Kexin Cui; Li Kong; Conglian Yang; Zhiping Zhang
Journal:  Acta Pharm Sin B       Date:  2021-05-07       Impact factor: 11.413

Review 6.  Synthetic cells in biomedical applications.

Authors:  Wakana Sato; Tomasz Zajkowski; Felix Moser; Katarzyna P Adamala
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2021-11-01

7.  Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.

Authors:  Xin Luan; Hebao Yuan; Yudong Song; Hongxiang Hu; Bo Wen; Miao He; Huixia Zhang; Yan Li; Feng Li; Pan Shu; Joseph P Burnett; Nathan Truchan; Maria Palmisano; Manjunath P Pai; Simon Zhou; Wei Gao; Duxin Sun
Journal:  Biomaterials       Date:  2021-06-03       Impact factor: 12.479

8.  Dual-Ligand-Modified Liposomes Co-Loaded with Anti-Angiogenic and Chemotherapeutic Drugs for Inhibiting Tumor Angiogenesis and Metastasis.

Authors:  Fangqing Wang; Yanying Li; Hong Jiang; Chenglei Li; Zhaohuan Li; Cuiping Qi; Zhipeng Li; Zhiqin Gao; Bo Zhang; Jingliang Wu
Journal:  Int J Nanomedicine       Date:  2021-06-09

9.  Docetaxel loaded mPEG-PLA nanoparticles for sarcoma therapy: preparation, characterization, pharmacokinetics, and anti-tumor efficacy.

Authors:  Jianhua Chen; Eerdunbagena Ning; Zhijun Wang; Ziqi Jing; Guijie Wei; Xue Wang; Pengkai Ma
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

10.  Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.

Authors:  Wu Chen; Danlei Yu; Shi-Yong Sun; Feng Li
Journal:  Acta Biomater       Date:  2021-05-25       Impact factor: 10.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.